Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
9/4 05:38
Merck MRK announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer. The first patient has been dose...